1 / 40

Director’s Report to the National Advisory Council on Drug Abuse

This report provides an overview of the recent activities, budget updates, and initiatives undertaken by the National Institute on Drug Abuse (NIDA). It also highlights the research areas and staff appointments that will be addressed by the NIDA Director.

jamesperez
Download Presentation

Director’s Report to the National Advisory Council on Drug Abuse

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Director’s Report to the National Advisory Council on Drug Abuse May 22, 2003

  2. Glen R. Hanson, Ph.D., D.D.S. Acting NIDA Director December 1, 2001 to April 30, 2003 Thank you Glen!! Associate Director for Neuroscience and Translation

  3. What’s My Background? M.D. from National University of Mexico Residency in Psychiatry at New York University 20 Years Working in Addiction Research Prior to Becoming NIDA Director… Associate Director for Life Sciences, Brookhaven National Laboratory (BNL) Chairman, Medical Department, BNL Director of Nuclear Medicine, BNL Director of the NIDA-DOE Regional Neuroimaging Center at BNL Professor, Department of Psychiatry, SUNY-Stony Brook Associate Dean for the Medical School, SUNY-Stony Brook

  4. Brookhaven PET Group DOE/NIDA F. Telang, R. MacGregor, P. Carter, D. Schlyer, C. Shea, J. Gatley, S. Dewey, C. Redvanly, P. King L. Caligiuri, G-J Wang, M. Franceschi, Y-S Ding, J. Logan, N. Volkow, J. Fowler, R. Ferrieri, C. Wong (not shown) D. Alexoff, C. Felder, N. Pappas, D. Franceschi, N. Netusil, V. Garza, R. Carciello, D. Warner, M. Gerasimov

  5. DA DA DA DA DA Cocaine DA DA DA DA DA DA DA Reward Circuits DA D2 Receptor Availability DA DA Alcohol DA DA DA DA Reward Circuits Heroin control addicted Dopamine D2 Receptors are Lower in Addiction Non-Drug Abuser Drug Abuser

  6. Treatment Interventions Vulnerability to Addiction (Impact of Genetic and Environmental Influences) Prevention Research (Children and Adolescents) As NIDA Director… Some of the Research Areas I Intend To Address Include:

  7. Recent NIDA Staff Appointments/Changes Office of Science Policy and Communications (OSPC) Lucinda Miner, Ph.D. – Deputy Director, OSPC Division of Epidemiology, Services and Prevention Research (DESPR) Beverly Pringle, Ph.D. – Deputy Chief, Services Research Branch, DESPR Center for the Clinical Trials Network (CCTN) Karla Moras, Ph.D Division of Treatment Research & Development (DTR&D) Mary Ann Stephens, Ph.D. Office of Extramural Affairs (OEA) Eliane Lazar-Wesley, Ph.D.

  8. Director’s Report to the National Advisory Council on Drug Abuse FY 2004 and Beyond What’s New at NIH? Budget Update Recent NIDA Activities

  9. What’s New at NIH?

  10. THE NIH ROADMAP An Agency-Wide Effort To Identify the Critical Roadblocks and Knowledge Gaps That Constrain Rapid Advances in Biomedical Research Progress

  11. NIH Roadmap NATIONAL CLINICAL RESEARCH NETWORKS RE-ENGINEERING THE CLINICAL RESEARCH ENTERPRISE Form a sustained, efficient infrastructure Rapidly initiate large clinical trials Rapidly move effectiveness data into the community Provide information to patients, families & advocacy groups THEMES GOALS NEW PATHWAYS TO DISCOVERY RESEARCH TEAMS OF THE FUTURE TRANSLATIONAL RESEARCH INFRASTRUCTURE INTEGRATED, MULTIDISCIPLINARY & DIVERSE WORKFORCE

  12. NIH Roadmap Initiatives New Pathways to Discovery New Approaches Building Blocks for Biology Biological Pathways and Networks Regenerative Medicine Nancy Pilotte Barry Hoffer Technologies Structural Biology Bioinformatics & Computational Biology Molecular Libraries Nanotechnology Molecular Imaging Glen Hanson & David Shurtleff Nora Volkow (Co-chair)

  13. NIH Roadmap Initiatives Re-engineering the Clinical Research Enterprise Research Teams of the Future Multi-disciplinary Research Teams Public/Private Partnerships High-risk Research Wilson Compton Glen Hanson & Frank Vocci Teri Levitin Translational Research Integrated Clinical Research Networks Clinical Research Workforce Training Clinical Research Informatics Glen Hanson & Bill Corrigall Don Vereen

  14. Budget Update

  15. 2001Actual 2002Actual 2003Estimate 2004P.B. $537,075 $606,830 $680,603 $660,109 $245,397 $278,372 $315,011 $301,612 $782,472 $885,202 $995,614 $961,721 +12.2% +13.1% +3.7% +8.6% NIDA BUDGET (Thousands) NonAIDS AIDS TOTAL Increase Over Prior Year

  16. Recent NIDA Activities

  17. Highlights of Recent Meetings and Events

  18. The 7th Annual PRISM Awards May 8, 2003

  19. To Commemorate Brain Awareness Week At NIH

  20. In Memory of Dr. Roger Brown Associate Director for Neuroscience Division of Neuroscience and Behavioral Research, NIDA

  21. Beyond the Clinic Walls: Expanding Mental Health, Drug & Alcohol Services Research Outside the Specialty Care System Sponsored by: NIMH, NIDA & NIAAA March 10-12, 2003

  22. Recent Meetings/Events Stem Cells: Opportunities for Drug Abuse Research? Smoking Cessation Pharmacotherapy: Accelerating Discovery to Delivery (with NCI and NIAAA at SRNT) Smoking Cessation in Opioid Dependent Patients Workshop (at AATOD Meeting) Drug Use and Suicidal Behavior Effectiveness of NIDA’s Public Information Publications Advisory Panel Dr. Lonnie E. Mitchell National HBCU Substance Abuse Research Conference (Co-sponsor) First Annual CyberTherapy Conference (Co-sponsor) Drug Abuse As A Gender Issue (at ASPET Meeting) Special Event Program at (SRCD) CTN National Steering Committee Meetings January 25-30, 2003 – Miami, FL March 23-28, 2003 – Albuquerque, NM

  23. NIDA National Institute on Drug Abuse New Program Announcements (PAs) and Requests for Applications (RFAs) Issued With Other NIH Components

  24. New PAs With Other NIH Components Planning Grants to Organize Programs for International Clinical, Operational and Health Services Research Training for AIDS and Tuberculosis (PAR-03-073) Gene Discovery for Complex Neurological and Neuro- behavioral Disorders (PAS-03-092) (with NINDS, NIA and National Institute of Environmental Health Sciences (NIEHS)) Centers for AIDS Research: D-CFAR, CFAR (PAR-03-089) Research on Children Exposed to Violence (PAR-03-096) Innovations in Biomedical Computational Science and Technology (PAR-03-106) NIH Small Research Grants Program (R03) (PA-03-108) NIH Exploratory/Developmental Research Grant Award (R21) (PA-03-107)

  25. New RFAs With Other NIH Components Clinical Research Education and Career Development (CRECD) in Minority Institutions (RR-03-007)

  26. DHHS NIH SAMHSA NIDA NIDA Translate Research Findings Into Relevant Clinical Practice

  27. NIDA/SAMHSA Science to Services Efforts NIH Grant Writing Technical Assistance NIDA Funding the Center for Substance Abuse Treatment’s (CSAT) Addiction Technology Transfer Centers (ATTC) and the Center for Substance Abuse Prevention’s (CSAP) Community Coalitions Analysis NIDA Providing Implementation-Ready Interventions to CSAT and CSAP CSAT and CSAP Co-funding NIDA’s: Criminal Justice Initiative Multisite Community Prevention Trials Linking NIDA and CSAT Grant Programs

  28. FY 2004 and Beyond

  29. Division of Neuroscience and Behavioral Research (DNBR) 5-Year View Transdisciplinary Approaches New Technology, Models, Paradigms Genetics/Vulnerability and Developmental Processes

  30. DNBR New Initiatives Tobacco Addiction Proteomics Adolescents and Drug Abuse Drug Abuse Relapse

  31. Division of Treatment Research and Development (DTR&D) 5-Year View Shift in Medications Development Efforts from Opiates to Stimulants and Nicotine Foster Relationships With Pharmaceutical Industry Revive Medical Involvement in Drug Abuse Treatment New Directions for Behavioral Therapy Development

  32. DTR&D New Initiatives Access to Chemical and Molecular Libraries Integration of HIV & Infectious Disease Risk Reduction Interventions into Behavioral Treatments Neurodevelopment/Pediatric Neuroimaging Translational Brain Imaging Centers

  33. Division of Epidemiology, Prevention and Services Research (DESPR) 5-Year View Services System Studies for Prevention and Treatment In Order to Improve Public Health Outcomes (i.e. Science to Service Programs) Environment-Gene Interaction Studies Transdisciplinary Research: Applying Concepts and Methodologies from Allied Fields to “Real Settings” Public Health Research (e.g. Behavioral Economics and Neuroscience)

  34. DESPR New Initiatives Prevention and Treatment of Drug Abuse in Primary Care Settings Novel Approaches to Phenotyping Drug Abuse Prevention Programs Aimed at Young Adults Family-Based Prevention Systems

  35. Center on AIDS and Other Medical Consequences of Drug Abuse (CAMCODA) 5-Year View Better HIV/Drug Use Epidemiology and Prevention Studies Tailor HIV Treatment for Drug Abusers (Ethnicity, Gender, Culture) Drug Interaction International Research

  36. CAMCODA New Initiatives Hepatitis C Research Longitudinal Effects of Drug Use in Children International HIV/AIDS Prevention and Drug Abuse Treatment, Caribbean and China Women’s Health Research

  37. Center for the Clinical Trials Network (CCTN) 5-Year View Refinement of CTN’s Infrastructure and Mission Increase the Use of the CTN As A Platform for Training Enhance the Use of the CTN As A Platform for Additional Types of Research (Medications Development; HIV Prevention; Genetic Studies) Development of Clinical Practice Guidelines Revive Medical Involvement in Drug Abuse Treatment

  38. We Want Council’s Input! 1. Blue Ribbon Task Force 2. CTN 3. CAMCODA

More Related